This Femtech Company Is Pioneering Mucus Engineering As A New Alternative To Hormonal Birth Control
Cirqle Biomedical is a startup pioneering mucus engineering as a new alternative to hormonal birth control, based in Copenhagen, and its team recently demonstrated the first novel and effective approach to contraception since hormonal therapy was introduced more than 60 years ago. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 14, 2021 Category: Pharmaceuticals Authors: Marija Butkovic, Contributor Tags: ForbesWomen /forbeswomen Leadership /leadership Innovation /innovation Healthcare /healthcare Source Type: news

Benefits and Risks of Menopausal HT Among Women 50-59 Benefits and Risks of Menopausal HT Among Women 50-59
This report analyzes additional years of follow-up from the Women's Health Initiative hormone therapy trials, with a focus on participants 50-59 years of age. Does the new data change recommendations?American Journal of Epidemiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 6, 2021 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news

CTC mutations may predict outcomes in some castrate-resistant prostate cancer patients
(American Association for Cancer Research) Various genetic alterations in circulating tumor cells (CTCs) were associated with clinical outcomes and resistance to hormone therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 26, 2021 Category: Cancer & Oncology Source Type: news

Hormone Therapy May Reduce Nocturia After Menopause
TUESDAY, March 23, 2021 -- The percentage of postmenopausal women experiencing nocturia two or more times per night was lower among those who selected systemic hormone treatment compared with no treatment, according to a study published online March... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 23, 2021 Category: Pharmaceuticals Source Type: news

Prostate cancer uses metabolic switch to thrive after hormone therapy
(Duke University Medical Center) Studying the cellular metabolism of prostate cancer, a team of Duke Health-led researchers identified a key reason hormone therapies eventually fail, while also laying out a way to bypass the problem using an entirely new therapeutic approach. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 22, 2021 Category: Cancer & Oncology Source Type: news

Hormone therapy shown to reduce effects of nocturia in postmenopausal women
(The North American Menopause Society (NAMS)) CLEVELAND, Ohio (March 17, 2021)--As women age, they are more likely to wake up in the middle of the night to pass urine. The loss of estrogen during the menopause transition accelerates this problem, which is known as nocturia. A new study evaluated the effectiveness of different hormone therapies in managing the frequency of nocturia. Study results are published online today inMenopause, the journal of The North American Menopause Society (NAMS). (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 17, 2021 Category: International Medicine & Public Health Source Type: news

Hormone Therapy and Sexual Function During Menopausal Transition Hormone Therapy and Sexual Function During Menopausal Transition
Does hormonal therapy have a positive impact on sexual function in perimenopausal women?Menopause (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 8, 2021 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news

ACOG Advises on Care for Transgender Patients ACOG Advises on Care for Transgender Patients
The committee opinion provides guidance for ob-gyns. on topics including inclusivity, routine screening, fertility and reproductive issues, hormone therapy, medication use, and surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 2, 2021 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news

Molecular imaging determines effectiveness of novel metastatic breast cancer treatment
(Society of Nuclear Medicine and Molecular Imaging) Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy. According to research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography (PET) imaging using an imaging agent called 18F-fluoroestradiol can help to determine which patients could benefit from treatments that could spare them from unnecessary chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 16, 2021 Category: Cancer & Oncology Source Type: news

Genomic test helps estimate risk of prostate cancer metastasis, death
(Johns Hopkins Medicine) A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 11, 2021 Category: Cancer & Oncology Source Type: news

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.[1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cance...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said C...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Imaging identifies breast cancer patients unlikely to benefit from hormone therapy
(Washington University School of Medicine) Hormone therapy can be very effective for so-called estrogen receptor-positive breast cancer. But it only works for a little more than half of women who receive the treatment. In a small study, researchers at Washington University School of Medicine in St. Louis found that women whose tumors did not respond to a one-day estrogen challenge did not benefit from hormone therapy. The findings could help doctors choose treatments most likely to help their patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 2, 2021 Category: International Medicine & Public Health Source Type: news

No Need to Stop Estrogen in Transgender Women Before Gender-Affirming Surgery No Need to Stop Estrogen in Transgender Women Before Gender-Affirming Surgery
Transgender women can safely maintain their estrogen hormone therapy during gender-affirming surgery without an increased risk of venous thromboembolism (VTE), according to a new study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 20, 2021 Category: Surgery Tags: Diabetes & Endocrinology News Source Type: news

Estrogen Therapy Need Not Stop for Gender - Affirming Surgery
Authors find that perioperative venous thromboembolism rarely occurs, regardless of suspension of hormone therapy prior to surgery (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 19, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Surgery, Journal, Source Type: news

Estrogen Therapy Need Not Stop for Gender-Affirming Surgery
TUESDAY, Jan. 19, 2021 -- For transgender and gender nonbinary (TGNB) patients undergoing primary vaginoplasty, perioperative venous thromboembolism (VTE) occurs rarely, regardless of whether hormone therapy is suspended prior to surgery, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 19, 2021 Category: Pharmaceuticals Source Type: news

What Is Hormone Therapy Used For
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 12, 2021 Category: General Medicine Source Type: news

Sexual dysfunction hits some women harder than others as they age
(The North American Menopause Society (NAMS)) Sexual dysfunction often accompanies the menopause transition. Yet, not all women experience it the same. A new study identified the determinants that affect a woman's risk of sexual dysfunction and sought to determine the effectiveness of hormone therapy in decreasing that risk and modifying sexual behavior. Study results are published online in Menopause, the journal of The North American Menopause Society (NAMS). (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 6, 2021 Category: International Medicine & Public Health Source Type: news

With potential $4B Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs. The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer. Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 28, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

With potential $4B Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs. The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer. Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 28, 2020 Category: American Health Authors: Ron Leuty Source Type: news

With potential $4 billion Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs. The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer. Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 28, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

With potential $4 billion Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs. The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer. Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 28, 2020 Category: American Health Authors: Ron Leuty Source Type: news

New oral hormone drug for prostate cancer
The Food and Drug Administration has approved the use of a new oral hormone therapy drug, Relugolix, for treating advanced prostate cancer in men.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 22, 2020 Category: Endocrinology Source Type: news

FDA Approves First Oral Hormone Therapy for Advanced Prostate Cancer
MONDAY, Dec. 21, 2020 -- Orgovyx (relugolix) is now approved to treat advanced prostate cancer and is the first oral hormone therapy approved for this indication, the U.S. Food and Drug Administration announced Friday. As opposed to currently... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 21, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves First Oral Hormone Therapy for Treating Advanced Prostate Cancer
Today, the FDA approved the first oral hormone therapy for treating advanced prostate cancer. This therapy may eliminate some patients ’ need to visit the clinic for treatments that require administration by a health care provider. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 18, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Transgender women retain athletic advantages after hormone therapy
Transgender women retain athletic advantages over cisgender women for 1-2 years after starting gender-affirming hormone therapy, according to a study published in theBritish Journal of Sports Medicine.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 17, 2020 Category: Endocrinology Source Type: news

Oral hormone therapy shown to significantly alter metabolome of menopausal women
(University of Massachusetts Amherst) Groundbreaking research led by a team of scientists including a University of Massachusetts Amherst biostatistician shows that oral hormone therapy (HT) significantly alters the metabolome of postmenopausal women. This finding, which examined blood specimens from the landmark Women's Health Initiative (WHI) study, may help explain the disease risks and protective effects associated with different regimens of hormone therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 16, 2020 Category: International Medicine & Public Health Source Type: news

Leaders in Health Care: Dr. Seema Shah, Planned Parenthood of Maryland
Shah says telehealth has made many services more accessible, including gender-affirming hormone therapy, sexually transmitted infection screenings and birth control prescriptions. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 4, 2020 Category: American Health Authors: Amanda Yeager Source Type: news

Menopause hormone therapy: Does it cause vaginal bleeding?
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - December 2, 2020 Category: Consumer Health News Source Type: news

Transgender Americans use dangerous non-prescribed hormones
1 in 10 Transgender Americans may be using non-prescribed hormones that may cause serious health risks, as they aren’t insured or their insurance won’t cover costs of gender-affirming hormone therapy. CNN (Source: Society for Endocrinology)
Source: Society for Endocrinology - November 25, 2020 Category: Endocrinology Source Type: news

10% of transgender Americans may be using non-prescribed hormones
1 in 10 transgender Americans may be using non-prescribed hormones that may cause serious health risks, as they aren’t insured or their insurance won’t cover costs of gender-affirming hormone therapy. CNN (Source: Society for Endocrinology)
Source: Society for Endocrinology - November 25, 2020 Category: Endocrinology Source Type: news

Hormone Therapy for Prostate Cancer May Raise Heart Risks
Title: Hormone Therapy for Prostate Cancer May Raise Heart RisksCategory: Health NewsCreated: 11/20/2020 12:00:00 AMLast Editorial Review: 11/23/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 23, 2020 Category: Cancer & Oncology Source Type: news

Transgender Cancer Patients May Not Realize Treatment Can Interact With Their Hormone Therapy Transgender Cancer Patients May Not Realize Treatment Can Interact With Their Hormone Therapy
Transgender cancer patients often were not told of potential interactions between cancer treatment and gender-affirming hormone therapy, a case series reveals.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 20, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Hormone Therapy for Prostate Cancer May Raise Heart Risks
FRIDAY, Nov. 20, 2020 -- Hormone therapy can be a lifesaver for men with prostate cancer, but it also appears to put some at increased risk of heart problems, a new study reports. Long-term androgen deprivation therapy (ADT) increased the risk of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 20, 2020 Category: General Medicine Source Type: news

Prostate cancer: CRYM protein inhibits tumour growth
(Medical University of Vienna) Prostate cancer is caused by elevated hormone levels, and tumours are generally treated using hormone therapy. A research team headed by Lukas Kenner of MedUni Vienna in collaboration with David Heery from the University of Nottingham/UK and Sarka Pospisilova and Suzanne Turner of the University of Brno/Czech Republic have shown that the proteinμ-crystallin (CRYM) plays a significant part in tumour growth. The higher the levels of this protein that are present, the better the prognosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 18, 2020 Category: Cancer & Oncology Source Type: news

Female Hormone Rx Not Tied to Retinal Vascular Occlusion
TUESDAY, Nov. 17, 2020 -- Filling a prescription for female hormone therapy (FHT) is not associated with an increased risk for retinal artery occlusion (RAO) or retinal vein occlusion (RVO), according to a study published online Nov. 12 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 17, 2020 Category: Pharmaceuticals Source Type: news

Don't Miss Cardiovascular Risk Factors in Transgender Patients Don't Miss Cardiovascular Risk Factors in Transgender Patients
Cardiovascular disease risk is elevated among transgender individuals seeking gender-affirming hormone therapy, according to a retrospective study in 427 patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 13, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news

Breast Cancer and Hormone Therapy: What Do the New Data Mean? Breast Cancer and Hormone Therapy: What Do the New Data Mean?
A large British study takes another look at the question of the link between hormone replacement therapy and breast cancer.Medscape Ob/Gyn (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 13, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Transgender People Often Have Heart Risks: Study
THURSDAY, Nov. 12, 2020 -- Many transgender people who take hormone therapy have unaddressed risks for heart disease and stroke, a new study finds. These patients often have undiagnosed high blood pressure and high cholesterol, even in young... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 12, 2020 Category: General Medicine Source Type: news

AHA: CVD Risk Often Unaddressed for Transgender Population
TUESDAY, Nov. 10, 2020 -- Many transgender people receiving gender-affirming hormone therapy have cardiovascular disease risk factors, and a considerable proportion are not receiving appropriate therapies, according to a study presented at the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 10, 2020 Category: Pharmaceuticals Source Type: news

Under-insured transgender americans turn to riskier sources for gender-affirming hormones
(American Academy of Family Physicians) Transgender people who lack access to insurance coverage for gender-affirming hormone therapy are more likely to use hormones from sources other than a licensed prescriber, compared to those with insurance coverage. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 10, 2020 Category: International Medicine & Public Health Source Type: news

Transgender patients may have increased risk of cardiovascular diseases
According to a study presented at the American Heart Association Scientific Sessions 2020, transgender patients undergoing gender-affirming hormone therapy may have an increased risk of cardiovascular diseases.The Cardiology Advisor (Source: Society for Endocrinology)
Source: Society for Endocrinology - November 9, 2020 Category: Endocrinology Source Type: news

Breast cancer recurs after treatment because hormone therapy only puts some cells to "sleep," suggests study
(Natural News) Scientists have long debated whether the hormone therapy that is used to treat breast cancer actually kills all of the breast cancer cells completely or simply puts them into a dormant “sleeper” state. However, a new study has found that both camps could be right and that these drugs kill some cells while... (Source: NaturalNews.com)
Source: NaturalNews.com - November 4, 2020 Category: Consumer Health News Source Type: news

Breast Cancer Surgery Feasible for Most Fit Older Women
Hormone therapy alone may be as good as surgery if life expectancy is less than four years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 23, 2020 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Surgery, Geriatrics, Conference News, Source Type: news

Advanced prostate cancer has an unexpected weakness that can be targeted by drugs
(Kanazawa University) Kanazawa University researchers reported that the SUCLA2 gene is frequently involved in the deletion of the tumor suppressor gene RB1 in advanced prostate cancer. RB1 deletion makes cells resistant to hormone therapy but SUCLA2 deletion induces a metabolic weakness. The study showed that thymoquinone selectively killed SUCLA2-deficient prostate cancer cellsinvitro andinvivo. The findings highlight a vulnerability of advanced prostate cancer cells that can be targeted by drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 7, 2020 Category: Cancer & Oncology Source Type: news

Scientists discover potential new treatment for breast cancer
A team of Irish scientists may have discovered a potential new treatment option for patients with breast cancer who are resistant to hormone therapy, according to a study published in the journalCancer Research.Independent.ie (Source: Society for Endocrinology)
Source: Society for Endocrinology - October 5, 2020 Category: Endocrinology Source Type: news

Judgment Free Online Platform Key to Helping Suicidal People, Says Survivor
A suicide survivor shares her story of how an online community helped her overcome anxiety and depression. Credit: Unsplash / Dan M By Fairuz AhmedNEW YORK, Sep 28 2020 (IPS) Romana Hoque had it all, a comfortable life, a happy family. Despite this, the 43-year-old second-generation immigrant from Indonesia living in the United States was depressed enough to contemplate suicide. Hoque, in an exclusive interview with Inter Press Service (IPS), said despite her comfortable life, not being able to conceive resulted in her feeling so depressed that she tried to take her own life. She shared her story during September – ...
Source: IPS Inter Press Service - Health - September 28, 2020 Category: International Medicine & Public Health Authors: Fairuz Ahmed Tags: Aid Featured Gender Global Headlines Health TerraViva United Nations Fuzia 2020 Source Type: news

New hormone therapies for hot flashes offer enhanced benefits and minimized risk
(The North American Menopause Society (NAMS)) Hormone therapy remains the best proven method for managing menopause symptoms such as hot flashes. Research continues, however, in the area to identify novel approaches to estrogen therapy that minimize any associated risks. Dr. Hugh Taylor from Yale School of Medicine will discuss some of the latest developments, including fetal estrogens, during the 2020 Pre-Meeting Symposium of The North American Menopause Society (NAMS). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 28, 2020 Category: Cancer & Oncology Source Type: news

How hormone therapy slows progression of atherosclerosis
(The North American Menopause Society (NAMS)) As one of the most common treatments for effectively managing menopause symptoms, hormone therapy (HT) is also known to provide multiple health benefits, including slowing the progression of atherosclerosis. A study based on Early Versus Late Intervention Trial With Estradiol (ELITE) data evaluated the underlying mechanism of such benefit and will be presented during the 2020 Virtual Annual Meeting of The North American Menopause Society (NAMS), opening on September 28. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - September 28, 2020 Category: International Medicine & Public Health Source Type: news